scholarly journals affron®, a standardised extract from saffron (Crocus sativus L.) for the treatment of youth anxiety and depressive symptoms: A randomised, double-blind, placebo-controlled study

2018 ◽  
Vol 232 ◽  
pp. 349-357 ◽  
Author(s):  
Adrian L. Lopresti ◽  
Peter D. Drummond ◽  
Antonio M. Inarejos-García ◽  
Marin Prodanov
Phytomedicine ◽  
2006 ◽  
Vol 13 (4) ◽  
pp. 215-221 ◽  
Author(s):  
C. Randløv ◽  
J. Mehlsen ◽  
C.F. Thomsen ◽  
C. Hedman ◽  
H. von Fircks ◽  
...  

2019 ◽  
Vol 33 (11) ◽  
pp. 1415-1427 ◽  
Author(s):  
Adrian L Lopresti ◽  
Stephen J Smith ◽  
Sean D Hood ◽  
Peter D Drummond

Background: As a stand-alone intervention, saffron has efficacy for the treatment of mild-to-moderate depression. However, research as an adjunct agent is limited. Aims: The effects of saffron as an adjunct to pharmaceutical antidepressants in adults with persistent depression was investigated. Methods: In this eight-week, randomised, double-blind, placebo-controlled study, adults with persistent depression, currently taking a pharmaceutical antidepressant were given a placebo or a saffron extract (affron®, 14 mg b.i.d.). Primary outcome measures included the clinician-rated Montgomery–Åsberg Depression Rating Scale (MADRS) and self-rated MADRS (MADRS-S). Secondary outcome measures included the Antidepressant Side-Effect Checklist (ASEC) and Short Form-36 Health Survey (SF-36). Results: Of the 160 participants enrolled, 139 provided usable data. Based on the MADRS, depressive symptoms decreased more in participants taking saffron compared with a placebo, with reductions of 41 and 21%, respectively ( p = 0.001). However, scores on the MADRS-S decreased 27 and 26% in the saffron and placebo conditions, respectively ( p = 0.831). Saffron was associated with a greater reduction in adverse effects of antidepressants ( p = 0.019), although this was non-significant after covarying for baseline values ( p = 0.449). Quality of life improved in both groups with no significant between-group differences ( p = 0.638). Conclusion: Adjunctive administration of a standardised saffron extract (affron®) for eight weeks was associated with a greater improvement in depressive symptoms as measured by the clinician-rated MADRS but not the self-report MADRS-S. Given the conflicting results, further research is needed to clarify the clinical benefits of saffron as an adjunctive treatment for adults with persistent depressive symptoms despite antidepressant drug treatment.


2018 ◽  
Vol In Press (In Press) ◽  
Author(s):  
Shonaz Ahmadi Khatir ◽  
Ayatollah Bayatian ◽  
Abolfazl Barzegari ◽  
Neda Roshanravan ◽  
Abdolrasoul Safaiyan ◽  
...  

2004 ◽  
Vol 171 (4S) ◽  
pp. 234-234 ◽  
Author(s):  
Harin Padma-Nathan ◽  
Jae Seung Pacik ◽  
Byoung Ok Ahn ◽  
Kyung Koo Kang ◽  
Mi Young Bahng ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document